Oct 1 (Reuters) - MITHRA PHARMACEUTICALS SA MITRA.BR :
- MITHRA SIGNS LANDMARK CONTRACT FOR ESTELLE® IN THE UNITED STATES WITH MAYNE PHARMA
- MITHRA ELIGIBLE FOR LICENSE FEES OF AT LEAST USD 295 MILLION
- MITHRA TO BE AWARDED 9.6% EQUITY STAKE ACROSS TWO TRANCHES IN MAYNE PHARMA
- POTENTIAL GROSS REVENUES IN MITHRA'S WORST-CASE SCENARIO AT A MINIMUM OF EUR 4,5 BILLION, WHICH REPRESENTS MORE THAN TWICE SIZE OF EUROPEAN DEAL
- CDMO CROSS FERTILIZATION OPPORTUNITIES FOR BOTH COMPANIES
- PARTIES WILL WORK TOGETHER ON REGULATORY SUBMISSION PLANNED BY END 2019 WITH PROJECTED COMMERCIAL LAUNCH OF ESTELLE® IN H1 2021
News: MYX Mithra Signs Landmark Contract For Estelle® With Mayne Pharma
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.25 |
Change
-0.150(2.78%) |
Mkt cap ! $426.5M | |||
| Open | High | Low | Value | Volume |
| $5.35 | $5.41 | $5.19 | $1.239M | 231.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $5.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.36 | 1000 | 1 |
View Market Depth
| Last trade - 16.11pm 25/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |